Exploring CBX-12-101: a First-in-Human Study of CBX-12, an AlphalexTM Peptide Drug Conjugate (PDC) in Patients With Advanced or Metastatic Solid Tumors

Time: 9:00 am
day: Conference Day 2


• AlphalexTM peptides undergo a conformational change in acidic environments facilitating targeted delivery of highly potent anti-cancer therapeutics

• Cybrexa PDCs do not require expression of any cell surface proteins

• Analyzing the activity seen with 3 different schedules in multiple tumor types